Therefore, FGF21 shows therapeutic potential to treat obesity-related metabolic complications, including hyperglycemia, insulin resistance, and non-alcoholic fatty liver disease (NAFLD)24–27. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.